- Home
- AAMI vs AUPH Comparison
AAMI vs AUPH Comparison
Compare AAMI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- AUPH
- Stock Information
- Founded
- AAMI 1980
- AUPH 1993
- Country
- AAMI United States
- AUPH Canada
- Employees
- AAMI N/A
- AUPH N/A
- Industry
- AAMI Investment Managers
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- AAMI Finance
- AUPH Health Care
- Exchange
- AAMI Nasdaq
- AUPH Nasdaq
- Market Cap
- AAMI 1.1B
- AUPH 1.1B
- IPO Year
- AAMI N/A
- AUPH 1999
- Fundamental
- Price
- AAMI $38.79
- AUPH $8.96
- Analyst Decision
- AAMI Hold
- AUPH Strong Buy
- Analyst Count
- AAMI 3
- AUPH 2
- Target Price
- AAMI $30.33
- AUPH $11.50
- AVG Volume (30 Days)
- AAMI 282.3K
- AUPH 2.0M
- Earning Date
- AAMI 07-31-2025
- AUPH 07-31-2025
- Dividend Yield
- AAMI 0.10%
- AUPH N/A
- EPS Growth
- AAMI 46.05
- AUPH N/A
- EPS
- AAMI 2.40
- AUPH 0.27
- Revenue
- AAMI $519,799,999.00
- AUPH $247,295,000.00
- Revenue This Year
- AAMI $5.28
- AUPH $12.15
- Revenue Next Year
- AAMI $6.24
- AUPH $18.34
- P/E Ratio
- AAMI $16.18
- AUPH $33.62
- Revenue Growth
- AAMI 18.00
- AUPH 29.20
- 52 Week Low
- AAMI $21.49
- AUPH $5.20
- 52 Week High
- AAMI $39.85
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- AAMI N/A
- AUPH 63.15
- Support Level
- AAMI N/A
- AUPH $8.73
- Resistance Level
- AAMI N/A
- AUPH $9.10
- Average True Range (ATR)
- AAMI 0.00
- AUPH 0.44
- MACD
- AAMI 0.00
- AUPH 0.13
- Stochastic Oscillator
- AAMI 0.00
- AUPH 92.56
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.